Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma

NCT02923531 is registered in ClinicalTrials.gov with X4 Pharmaceuticals as lead sponsor.

NCT NCT02923531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02923531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
X4 Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
December 7, 2016
Completion date
August 8, 2018
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma